APH:LSE-Alliance Pharma plc (GBX)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | LSE

Last Closing Price

GBX 74.00

Change

0.00 (0.00)%

Market Cap

GBX 0.39B

Volume

1.44M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally. The company acquires, markets, and distributes pharmaceutical and other medical products. It owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The company also offers medical devices, food supplements, and cosmetics. In addition, the company provides its products under the Kelo-Cote, Nizoral, MacuShield, Vamousse, Xonvea, Flamma Franchise, Aloclair, Hydromol, Forceval, Haemopressin, Optiflo, Oxyplastine, Ashton & Parsons, and Ametop brand names. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom. Address: Avonbridge House, Chippenham, United Kingdom, SN15 2BB

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

N/A

GBX5.94B 15.30 9.58
INDV:LSE Indivior PLC

N/A

GBX0.89B 3.30 1.17
BXP:LSE Beximco Pharmaceuticals Limite..

N/A

GBX0.43B 6.97 0.09
AMYT:LSE Amryt Pharma plc

N/A

GBX0.32B N/A N/A
BMK:LSE Benchmark Holdings plc

N/A

GBX0.29B N/A 32.98
STX:LSE Shield Therapeutics plc

N/A

GBX0.16B 53.33 215.95
EAH:LSE ECO Animal Health Group plc

N/A

GBX0.16B 17.98 9.29
AGY:LSE Allergy Therapeutics plc

N/A

GBX0.10B 15.48 6.31
DNL:LSE Diurnal Group plc

N/A

GBX0.09B N/A N/A
VLG:LSE Venture Life Group plc

N/A

GBX0.09B 32.48 16.04

ETFs Containing APH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.01% 15% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.01% 15% F 41% F
Trailing 12 Months  
Capital Gain 0.95% 31% F 61% D-
Dividend Return 0.73% 67% D+ 19% F
Total Return 1.69% 31% F 60% D-
Trailing 5 Years  
Capital Gain 28.14% 64% D 59% F
Dividend Return 10.40% 67% D+ 33% F
Total Return 38.54% 73% C 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 14.87% N/A N/A 78% C+
Dividend Return 2.20% N/A N/A 59% F
Total Return 17.08% N/A N/A 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 28.35% N/A N/A 37% F
Risk Adjusted Return 60.23% N/A N/A 72% C-
Market Capitalization 0.39B 79% C+ 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 35.98 25% F 22% F
Price/Book Ratio 1.46 86% B 40% F
Price / Cash Flow Ratio 10.99 29% F 31% F
EV/EBITDA 12.40 44% F 40% F
Management Effectiveness  
Return on Equity 4.18% 62% D- 57% F
Return on Invested Capital 8.96% 64% D 69% D+
Return on Assets 5.14% 77% C+ 76% C
Debt to Equity Ratio 28.10% 44% F 56% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.41 69% D+ 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.